Abstract 933P
Background
Merkel cell carcinoma (MCC) is a rare cutaneous neuroendocrine malignancy with a higher case-fatality rate than melanoma. The prognosis of MCC is complex and depends on many factors. In this study, we aimed to develop predictive survival models using machine learning (ML) algorithms and statistical techniques for patients with head and neck MCC.
Methods
Using a cohort of 1,372 patients diagnosed with MCC of the head and neck region in the United States between 2000 to 2019 sourced from the Surveillance, Epidemiology, and End Results (SEER) Program, we developed and evaluated a cox-proportional hazards (CPH) regression model, nine classification and regression ML models, and two ML-based survival models. Models were built with a total of 20 features, including demographic, cancer-related and treatment/surgery-related variables. Pre-processing, hyperparameter tuning, classification, regression, survival analyses, and model evaluations were performed using ‘scikit-learn', ‘scikit-survival', and ‘lifelines' packages on Python 3.80.
Results
The mean age of patients was (66.0). Most cases were diagnosed in stage I (n=723, 52.7%). Multivariate CPH model yielded a Concordance-Index (C-Index) = 0.700 on the test set, outperforming both random forest survival (C-Index = 0.591) and survival tree (C-Index = 0.582) algorithms. Of the nine classification models, gradient boosting classifier predicted the most accurate 2-year (AUC = 0.75; accuracy= 0.71) and 5-year (AUC = 0.75; accuracy = 0.68) survival. Additionally, the ridge- and lasso-regularized linear models performed the most accurate regression (RMSE = 1182.84, R2 = 0.2259; RMSE = 1184.70, R2 = 0.2234, respectively), and the gradient boosting regressor had acceptable predictions (RMSE = 1189.64, R2 = 0.2170) on test sets. According to the Shapley Additive Explanations (SHAP) value analysis, the most critical feature of these regression models was age, followed by sex and AJCC stage.
Conclusions
This study found that machine learning and statistical models provide reliable survival predictions for head and neck Merkel cell carcinoma, with models like gradient boosting classifiers having acceptable outputs, especially for 2-year survival.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1004P - Phase I/II trial of ASP1570, a novel diacylglycerol kinase ζ inhibitor, in patients with advanced solid tumors
Presenter: Daniel Olson
Session: Poster session 03
1005P - Microbial ecosystem therapeutics 4 (MET4) treatment mediates a humoral response in patients treated with immune checkpoint inhibition (ICI)
Presenter: Pavlina Spiliopoulou
Session: Poster session 03
1007P - Systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Initial results from a phase Ia study
Presenter: Kevin Harrington
Session: Poster session 03
1008P - Preliminary clinical PK and PD analysis of a phase I study of ZL-1218, a humanized anti-CCR8 IgG1 antibody, in patients with advanced solid tumors
Presenter: Ignacio Gil Bazo
Session: Poster session 03
1010P - Phase I dose-escalation study of HBM1020: A novel anti-B7H7 antibody in patients with advanced solid tumors
Presenter: Jason Henry
Session: Poster session 03
1011P - Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumors
Presenter: Desamparados Roda Perez
Session: Poster session 03
1012P - Safety, tolerability, and efficacy of nadunolimab in combination with pembrolizumab in patients with solid tumors
Presenter: roger cohen
Session: Poster session 03
1013P - A phase I study of rivoceranib combined with nivolumab in patients with unresectable or metastatic cancer
Presenter: Neal Chawla
Session: Poster session 03
1014P - Phase Ib trial results of safety, pharmacokinetics and pharmacodynamics of TU2218, TGFβ-RI and VEGF-R2 dual inhibitor in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Anthony Tolcher
Session: Poster session 03